Law firm Lifshitz, PC announces investigations into

0


NEW YORK, December 23, 2021 (GLOBE NEWSWIRE) –

Activision Blizzard, Inc. (NASDAQGS: ATVI)

Lifshitz Law Firm, PC announces that a class action complaint has been filed against Activision Blizzard alleging that the Defendants throughout the Class Period, made false and / or misleading statements and / or failed to disclose that : (1) Activision Blizzard has discriminated against women and minority employees; (2) Activision Blizzard fostered a pervasive “frat boy” corporate culture that continues to thrive; (3) numerous complaints regarding unlawful harassment, discrimination and retaliation were lodged with human resources staff and senior management and were not addressed; (4) the pervasive culture of harassment, discrimination and retaliation would seriously alter the operations of Activision Blizzard; (5) as a result of the above, the Company was exposed to a greater risk of regulatory and legal review and enforcement, including what would have a material adverse effect; (6) Activision Blizzard failed to notify shareholders that the California Department of Fair Employment and Housing (“DFEH”) had investigated Activision Blizzard for harassment and discrimination; and (7) accordingly, the Defendants’ statements regarding Activision Blizzard’s business, operations and prospects were materially false and misleading and / or lacked reasonable basis at all material times.

If you are an Activision Blizzard investor and would like additional information about our investigation, please complete the Information Request form or contact Joshua Lifshitz, Esq. by phone at (516)493-9780 or by email at [email protected]

Ardelyx Inc. (NASDAQGM: ARDX)

Lifshitz Law Firm, PC announces that a class action lawsuit has been filed on behalf of ARDX shareholders alleging that the defendants made materially false and misleading statements regarding tenapanor and the likelihood of it being approved by the FDA during the period of recourse, which led to significant losses for investors.

If you are an ARDX investor and would like additional information about our investigation, please complete the Information Request form or contact Joshua Lifshitz, Esq. by phone at (516)493-9780 or by email at [email protected]

Iterum Therapeutics plc (NASDAQCM: ITRM)

Lifshitz Law Firm, PC announces that a class action lawsuit has been filed against the ITRM alleging that the defendants made false and / or misleading statements and / or did not disclose that: (i) the sulopenem NDA was missing sufficient data to support the approval of treatment in adult women with UTI caused by susceptible microorganisms designated, proven or strongly suspected to be non-sensitive to a quinolone; (ii) therefore, it was unlikely that the FDA would approve sulopenem NDA in its current form; (iii) the defendants downplayed the seriousness of the problems and shortcomings associated with the NDA of sulopenem; and (iv) accordingly, the Company’s public statements were materially false and misleading at all material times.

If you are an ITRM investor and would like additional information about our investigation, please complete the Information Request form or contact Joshua Lifshitz, Esq. by phone at (516)493-9780 or by email at [email protected]

Zymergen Inc. (NASDAQGS: ZY)

Lifshitz Law Firm, PC announces that a class action lawsuit has been filed against Zymergen alleging that the defendants did not disclose to investors: (1) that, during the qualification process for Hyaline, key clients had encountered technical issues, including product shrinkage and incompatibility with customer processes; (2) that while the qualification process was essential in gaining market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) that as a result, the Company overestimated the demand for its products; (4) that due to the foregoing, the timing of delivery of the Company’s products was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) that due to the foregoing, the Defendants’ positive statements regarding the business, operations and prospects of the Company were materially misleading and / or lacked reasonable basis.

If you are a Zymergen investor and would like additional information about our investigation, please complete the Information Request form or contact Joshua Lifshitz, Esq. by phone at (516)493-9780 or by email at [email protected]

LAWYER ADVERTISING.© 2021 Lifshitz Law Firm, PC The law firm responsible for this announcement is Lifshitz Law Firm, PC, 1190 Broadway, Hewlett, New York 11557, Tel. : (516) 493-9780. Past results do not guarantee or predict a similar result with respect to any future matters.

Contact:

Joshua M. Lifshitz, Esq.
Law firm Lifshitz, CP
Telephone: 516-493-9780
Fax: 516-280-7376
E-mail: [email protected]


Share.

Comments are closed.